A
The Swiss pharmaceutical giant is entitled to recoup legal fees stemming from Harkonen’s 2009 felony conviction for hyping an autoimmune therapy made by InterMune Inc., the biotech company he led, a Delaware judge ruled. A Roche subsidiary bought InterMune for nearly $9 billion in 2014.
Vice Chancellor Nathan A. Cook, writing in a 51-page opinion, said Harkonen was improperly trying relitigate the conviction ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.